Rezolute, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2021; filed September 15, 2021. Although the request metadata refers to “2020 Q4,” this filing reports FY2021, with FY2020 as the comparable period.
Business context
Rezolute is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases related to chronic glucose imbalance. It had no commercial products and generated no revenue in either fiscal year. Its lead candidate, RZ358, was in Phase 2b development for congenital hyperinsulinism (HI); RZ402 was in Phase 1 development for diabetic macular edema (DME).
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $15.0 million | $14.5 million |
| General and administrative expense | $7.9 million | $6.1 million |
| Total operating expenses / operating loss | $22.9 million | $20.5 million |
| Net loss | $20.9 million | $20.3 million |
| Net loss per share, basic and diluted | $2.72 | $3.54 |
| Cash used in operating activities | $20.4 million | $24.2 million |
| Cash and cash equivalents at year-end | $41.0 million | $10.0 million |
Working capital was approximately $40.0 million at June 30, 2021. The company reported no product revenue, so a meaningful gross margin was not applicable. Total liabilities were $16.5 million, including $14.0 million of long-term debt net of discount and $0.4 million of embedded derivative liabilities. There was no current portion of the loan reported at year-end.
Changes versus FY2020
- Net loss increased by about $0.6 million, while operating expenses rose 12% to $22.9 million.
- R&D expense increased 4%; higher clinical-trial, personnel, and licensing costs were partly offset by lower consulting and outside-service costs. A $1.0 million ActiveSite milestone was triggered by FDA clearance of the RZ402 IND.
- G&A expense increased 30%, mainly from higher compensation and professional fees, including Nasdaq listing and advisory costs.
- Operating cash use declined by $3.7 million, partly because FY2020 included larger payments against Xoma license obligations.
- Financing cash inflows increased to $51.5 million, principally from the October 2020 equity placement and the first tranche of the April 2021 debt facility.
Liquidity, debt and financing
- The October 2020 private placement raised $41.0 million gross and approximately $37.4 million net. It included about 2.5 million common shares and warrants for about 0.8 million shares at $19.50 per share.
- In April 2021, Rezolute borrowed $15.0 million under a facility permitting up to $30.0 million in three tranches. The remaining $15.0 million is conditional on financing and clinical milestones; access is not assured.
- The loan’s stated rate was 8.87% at June 30, 2021; the effective rate after discounts and fees was 12.6%. Interest-only payments are permitted through at least May 1, 2023, and maturity is April 1, 2026. Substantially all assets, including intellectual property, secure the loan.
- The company must maintain at least $5.0 million in restricted cash beginning no later than December 31, 2021. Covenants, default provisions, fees, and collateral rights may constrain operations and financing flexibility.
- Management said cash on hand, together with proceeds available under financing arrangements, was expected to fund currently planned activities through at least September 30, 2022. This outlook depends partly on future financing access. Subsequent to year-end, the company reported approximately $1.5 million net from ATM sales through August 31, 2021 and $1.0 million from an August 2021 Lincoln Park agreement.
Outlook, risks and unusual items
- Clinical outlook: RIZE enrollment for RZ358 resumed in January 2021 after a COVID-19-related pause. Subject to pandemic conditions, management expected substantial enrollment completion by year-end 2021 and top-line data in Q1 2022. RZ402 Phase 1a topline results were described as positive; a Phase 1b study began in August 2021, with completion planned by Q1 2022. If results were favorable, management expected to advance toward a Phase 2a study in the second half of 2022.
- COVID-19: Management said FY2021 financial results were not significantly affected, but future impacts on trial enrollment, timelines, operations, suppliers, and capital access remained uncertain.
- Capital and execution risk: The company has a history of losses, an accumulated deficit of $168.1 million, no revenue, and expects continued operating losses. It may need additional capital beyond the stated runway; failure to obtain it could delay, scale back, or end programs.
- Other material risks: Clinical or regulatory failure, dependence on third-party manufacturers and trial providers, competition, intellectual-property challenges, and future commercialization and reimbursement uncertainty.
- Internal controls: Management concluded disclosure controls and internal control over financial reporting were not effective, citing two material weaknesses: inadequate segregation of duties and deficient treasury controls over authorized-share monitoring. Remediation was incomplete at year-end.
- Unusual reported items: FY2021 included a $1.8 million non-cash gain from changes in fair value of a derivative liability related to an authorized-share deficiency, which was cured in May 2021, and $0.5 million of employee retention credits. These items supported reported results but were not recurring product earnings.
- Ownership and dilution: Handok and Genexine held approximately 23% and 21%, respectively, as of September 2021. Outstanding options and warrants, additional equity facilities, and future capital raises may dilute shareholders.
Important facts for investors to verify
- Progress, enrollment, and timing for the RZ358 RIZE readout and the RZ402 Phase 1b results; confirm updates after the filing’s stated targets.
- Whether the conditions for the second and third loan tranches were met, including required financing, clinical milestones, and the restricted-cash requirement.
- Actual cash burn and financing proceeds after June 30, 2021, and whether management’s runway estimate remains supportable.
- Remediation of both material weaknesses and any subsequent changes in disclosure controls or financial reporting reliability.
- Potential dilution from warrants, stock options, ATM sales, and the Lincoln Park purchase agreement, as well as the effect of concentrated voting ownership.
- Future milestone and royalty obligations under the Xoma and ActiveSite licenses, and the impact of loan covenants, collateral, and default terms.